Table 3. Sensitivity analysis results (LY: life year, QALY: quality adjusted life year, ICER: incremental cost effectiveness ratio); Simulation 1: Exacerbation rate = -46% and Increase QALY = 0.125; Simulation 2: Exacerbation rate = -46% and COPD costs = -10%, Simulation 3: Exacerbation rate = -46% and COPD costs = -10% and Increase QALY = 0.125.

	Additional cost (€)	LY gained	QALY gained	ICER
Baseline case	14 102	0	0.8	17 583
Increase QALY = 0.03	14 102	0	0.267	52 750
Increase QALY = 0.17	14 102	0	1.515	9 309
Discount Qaly over time: 5%	14 102	0	0.77	18314
Discount Qaly over time: 50%	14102	0	0.72	17904
Exacerbation rate = -46%	18 533	0.962	1.181	15 689
COPD costs = -5%	10 453	0	0.802	13 033
COPD costs = -10%	6 803	0	0.802	8 482
Rehabilitation Costs = -50%	7 051	0	0.802	8 792
Rehabilitation_Costs +50%	21 154	0	0.802	26 375
Simulation 1	18 533	0.962	1.503	12 334
Simulation 2	10 834	0.962	1.181	9 171
Simulation 3	10 834	0.962	1.503	7 210